Multimodal Mechanism of Action of the GSK-3 Inhibitor 9-ING-41 (elraglusib) Includes an Immunomodulatory Component: Preliminary Results from the 1801 Phase 1/2 Trial
CANCER RESEARCH(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
CANCER RESEARCH(2023)